Telomir Pharmaceuticals, Inc. Common Stock (TELO) - Total Liabilities
Based on the latest financial reports, Telomir Pharmaceuticals, Inc. Common Stock (TELO) has total liabilities worth $827.31K USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Telomir Pharmaceuticals, Inc. Common Sto (TELO) net asset momentum to track the company's year-over-year net asset growth rate.
Telomir Pharmaceuticals, Inc. Common Stock - Total Liabilities Trend (2021–2025)
This chart illustrates how Telomir Pharmaceuticals, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Telomir Pharmaceuticals, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Telomir Pharmaceuticals, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mirae Asset Daewoo Special Purpose Acquisition Company 4 Co. Ltd
KQ:333430
|
Korea | ₩38.62 Billion |
|
Weir Group PLC
LSE:WEIR
|
UK | GBX2.62 Billion |
|
Western Energy Services Corp.
TO:WRG
|
Canada | CA$106.06 Million |
|
MFEC PCL
BK:MFEC
|
Thailand | ฿3.54 Billion |
|
RGB International Bhd
KLSE:0037
|
Malaysia | RM432.90 Million |
|
Elite Naturel Organik Gida Sanayi ve Ticaret AS
IS:ELITE
|
Turkey | TL408.23 Million |
|
Les Docks des Pétroles d-Ambès - SA
PA:DPAM
|
France | €22.56 Million |
|
Say Yenilenebilir Enerji Ekipmanları Sanayi ve Ticaret Anonim Şirketi
IS:SAYAS
|
Turkey | TL844.16 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Telomir Pharmaceuticals, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Telomir Pharmaceuticals, Inc. Common Sto market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Telomir Pharmaceuticals, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Telomir Pharmaceuticals, Inc. Common Stock (2021–2025)
The table below shows the annual total liabilities of Telomir Pharmaceuticals, Inc. Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $1.43 Million | +109.70% |
| 2024-09-30 | $680.97K | -49.01% |
| 2023-09-30 | $1.34 Million | +35.45% |
| 2022-09-30 | $986.01K | +613.82% |
| 2021-09-30 | $138.13K | -- |
About Telomir Pharmaceuticals, Inc. Common Stock
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macu… Read more